Bladder Cancer

The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk non–muscle-invasive bladder cancer.

Removing more lymph nodes during surgery may also increase the risk for death after surgery in muscle-invasive bladder cancer.

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed after checkpoint inhibitors.

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.

Fatigue is a common side effect that may linger for years following cancer treatment. Experts and survivors talk about ways to help find a balance between life and fatigue.

Patients with locally advanced muscle-invasive bladder cancer may benefit from dose-dense gemcitabine and cisplatin.

Considering nutrition and frailty earlier on may help patients achieve better health-related quality of life during kidney cancer and bladder cancer.

Certain genetic mutations were associated with better responses to presurgical chemotherapy in muscle-invasive bladder cancer.

Patients saw improved event-free survival and overall survival with presurgical Imfinzi and chemotherapy followed by surgery and postsurgical Imfinzi.

Patients who received systemic therapy at the end of life did not have longer overall survival averages than those who did not receive therapy at end of life.

Antibody-drug conjugates represent a paradigm shift for patients with cancer and providers.

Padcev and Keytruda improve survival and progression among patients with bladder cancer, but don’t adversely impact pain, functioning or quality of life.

For patients with cisplatin-ineligible bladder cancer, presurgical Padcev decreased the cancer stage without leading to delays in surgery.

The FDA has approved several treatments for patients with solid tumors. Here are five recently approved treatments.

A novel delivery system of gemcitabine called TAR-200 led to promising responses in certain patients with non-muscle-invasive bladder cancer.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer.

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

The survival benefit observed with Padcev plus Keytruda was “unlike anything we’d seen before” for advanced bladder cancer, according to an expert.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

Treatment with immune checkpoint inhibitors has improved survival outcomes for patients with metastatic bladder cancer, compared with chemotherapy.

Quality of life, sexual outcomes and self-image should be considered before choosing a treatment option for muscle-invasive bladder cancer, an expert said.

From Oliva Munn and Christine Brinkley discussing their cancer to Donnie Iris returning to the stage after his experience with the disease, here is what’s happening in the oncology space this week.

The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.

A phase 2 trial showed that Trodelvy plus Keytruda had a high response rate with lasting responses, emphasizing “potential additive or synergistic effects,” an expert said.